Efficacy of vaginally applied estrogen, testosterone, or polyacrylic acid on sexual function in postmenopausal women: A randomized controlled trial

Journal of Sexual Medicine

Volumn 11, Issue 5, 2014, Pages 1262-1270

  Fernandes, Tatiane ^a   Costa Paiva, Lucia Helena ^a   Pinto Neto, Aarão Mendes ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Hormones; Sexuality; Vaginal atrophy

Indexed keywords

CONJUGATED ESTROGEN; K Y JELLY; LUBRICATING AGENT; POLYACRYLIC ACID; TESTOSTERONE PROPIONATE; UNCLASSIFIED DRUG; VAGIDRAT;

ACNE; ADULT; AGED; ANDROGEN THERAPY; ARTICLE; CLITORIS HYPERTROPHY; COITUS; CONTROLLED STUDY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; DYSPAREUNIA; ESTROGEN THERAPY; FEMALE; FEMALE SEXUAL DYSFUNCTION; FEMALE SEXUAL FUNCTION INDEX; FOLLOW UP; HAIR GROWTH; HUMAN; MAJOR CLINICAL STUDY; MONOTHERAPY; ORGASM; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SELF REPORT; SEXUAL AROUSAL; SEXUAL BEHAVIOR; SEXUAL FUNCTION; SEXUAL SATISFACTION; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; VAGINA ATROPHY; VAGINAL LUBRICATION; VAGINITIS;

HORMONES; SEXUALITY; VAGINAL ATROPHY;

ACRYLIC RESINS; ADMINISTRATION, INTRAVAGINAL; ADULT; AGED; ANDROGENS; CELLULOSE; ESTROGEN RECEPTOR MODULATORS; ESTROGENS; FEMALE; GLYCEROL; HUMANS; LIBIDO; MIDDLE AGED; ORGASM; PHOSPHATES; POSTMENOPAUSE; PROPYLENE GLYCOLS; SEXUAL BEHAVIOR; TESTOSTERONE; VAGINAL CREAMS, FOAMS, AND JELLIES;

EID: 84899482759     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/jsm.12473     Document Type: Article

References (35)

1. Nappi RE. New attitudes to sexuality in the menopause: Clinical evaluation and diagnosis. Climacteric 2007;10:105-108.
2. The North American Menopause Society. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women 2007. Position Statement of the North American Menopause Society. Menopause 2007;14:357-369.
3. Nappi RE, Albani F, Valentino V, Polatti F, Chiovato L, Genazzani AR. Aging and sexuality in women. Minerva Ginecol 2007;59:287-298.
4. Avis NE, Zhao X, Johannes CB, Ory M, Brockwell S, Greendale GA. Correlates of sexual function among multi-ethnic middle-aged women: Results from the Study of Women's Health Across the Nation (SWAN). Menopause 2005;12:385-398.
5. Kingsberg AS, Wysocki S, Magnus L, Krychman ML. Vulvar and vaginal atrophy in postmenopausal women: Findings from the REVIVE (REal Women's Views of Treatment Options for Menopausal Vaginal ChangEs) survey. J Sex Med 2013;10:1790-1799.
6. Nappi RE, Lachowsky M. Menopause and sexuality: Prevalence of symptoms and impact on quality of life. Maturitas 2009;63:138-141.
7. Castelo Branco C, Cancel MJ, Villena J, Nahales F, Julia MD. Management of post-menopausal vaginal atrophy and atrophic vaginitis. Maturitas 2005;52:46-52.
8. Suckling J, Lethaby A, Kennedy R. Local estrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev 2006;(06):CD001500, doi: 10.1002-14651858.CD 001500.pub4.
9. Palacios S, Castelo-Branco C, Cancelo MJ, Vazquez F. Low dose vaginally administered estrogens may enhance local benefits of systemic therapy in the treatment of urogenital atrophy in postmenopausal women on hormone therapy. Maturitas 2005;50:98-104.
10. Nappi RE, Kingsberg S, Maamari R, Simon J. The CLOSER (Clarifying Vaginal Atrophy's Impact on Sex and Relationships) survey: Implications of vaginal discomfort in postmenopausal women and in male partners. J Med Sex 2013;10:2232-2241. doi: 10.1111/jsm.12235.
11. Labrie F, Cusan FL, Gomez JL. Effect of one-week treatment with vaginal estrogen preparations on serum estrogen levels in postmenopausal women. Menopause 2009;16:30-36.
12. Glaser R, York AE, Dimitrakakis C. Beneficial effects of testosterone therapy in women measured by the validated Menopause Rating Scale. Maturitas 2011;68:355-361.
13. Lobo R, Rosen RC, Yang HM, Block B, Van der Hoop RG. Comparative effects of oral esterified estrogens with and without methyltestosterone on endocrine profiles and dimensions of sexual function in postmenopausal women with hypoactive sexual desire. Fertil Steril 2003;79:1341-1352.
14. Hubayter Z, Simon JA. Testosterone therapy for sexual dysfunction in postmenopausal women. Climacteric 2008;11:181-189.
15. Raghunandan C, Agrawal S, Dubey P, Choudhury M, Jain A. A comparative study of the effects of local estrogen with or without local testosterone on vulvovaginal and sexual dysfunction in postmenopausal women. J Sex Med 2010;7:1284-1290.
16. Witherby S, Johnson J, Demers L, Mount S, Littenberg B, Maclean CD, Wood M, Muss H. Topical testosterone for breast cancer patients with vaginal atrophy related to aromatase inhibitors: A phase I-II study. Oncologist 2011;16:424-431.
17. Nachtigall LE. Comparative study: Replens vs. local estrogen in menopausal women. Fertil Steril 1994;61:178-180.
18. Bygderman M, Swahn ML. Replens vs. dienoestrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women. Maturitas 1996;23:259-263.
19. Van der Laak JA, de Bie LM, Leeuw H, Wilde PC, Hanselaar AG. The effect of Replens® on vaginal cytology in the treatment of postmenopausal atrophy: Cytomorphology vs. computerised cytometry. J Clin Pathol 2002;55:446-451.
20. Lara LA, Useche B, Ferriani RA, Reis RM, de Sá MF, de Freitas MM, Rosa e Silva JC, Rosa e Silva AC. The effects of hypoestrogenism on the vaginal wall: Interference with the normal sexual response. J Sex Med 2009;6:30-39.
21. Rosen R, Brown C, Heiman J, Leiblum S, Meston C, Shabsigh R. The Female Sexual Function Index (FSFI): A multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther 2000;26:191-208.
22. Thiel R, Dambros M, Palma PC, Thiel M, Ricceto CL, Ramos MF. Translation into Portuguese, cross-national adaptation and validation of the Female Sexual Function Index. Rev Bras Ginecol Obstet 2008;30:504-510.
23. Gass MLS, Bachman GA, Goldstein SR, Kingsberg SA, Liu JH, Martens MG, Pace DT, Pinkerton JV, Shifren JL. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause 2013;20:888-902.
24. Labrie F, Archer DF, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, Baron M, Ayotte N, Moreau M, Dubé R, Cote I, Labrie C, Lavoie L, Berger L, Gilbert L, Martel C, Balser J. Intravaginal dehydroepiandrosterone (prasterone), a highly efficient treatment of dyspareunia. Climacteric 2011;14:282-288.
25. Bachmann GA, Leiblum SR. The impact of hormones on menopausal sexuality: A literature review. Menopause 2004;11:120-130.
26. Hage G, Eden JA, Manga RZ. A double-blind, randomized, placebo-controlled trial of the effect of testosterone cream on the sexual motivation of menopausal hysterectomized women with hypoactive sexual desire disorder. Climacteric 2007;10:335-343.
27. Berger L, El-Alfy M, Martel C, Labrie F. Effects of dehydroepiandrosterone, Premarin and Acolbifene on histomorphology and sex steroid receptors in the rat vagina. J Steroid Biochem Mol Biol 2005;96:201-215.
28. Baldassarre M, Perrone AM, Giannone FA, Armillotta F, Battaglia C, Costantino A, Venturoli S, Meriggiola MC. Androgen receptor expression in the human vagina under different physiological and treatment conditions. Int J Impot Res 2013;25:7-11.
29. Pessina MA, Hoyt RF Jr, Goldstein L, Traish AM. Differential regulation of the expression of estrogen, progesterone and androgen receptors by sex steroid hormones in the vagina: Immunohistochemical studies. J Sex Med 2006;3:804-814.
30. Schover LR. Androgen therapy for loss of desire in women: Is the benefit worth the breast cancer risk? Fertil Steril 2008;90:129-140.
31. Freedman M, Kaunitz AM, Reape KZ, Hait H, Shu H. Twice-weekly synthetic conjugated estrogens vaginal cream for the treatment of vaginal atrophy. Menopause 2009;16:735-741.
32. Simon JA, Nappi RE, Kingsberg SA, Maamari R, Brown V. Clarifying Vaginal Atrophy's Impact on Sex and Relationships (CLOSER) survey: Emotional and physical impact of vaginal discomfort on North American postmenopausal women and their partners. Menopause 2014;21:137-142.
33. Seed M, Sands RH, McLaren M, Kirk G, Darko D. The effect of hormone replacement therapy and route of administration on selected cardiovascular risk factors in post-menopausal women. Fam Pract 2000;17:497-507.
34. Stika CS. Atrophic vaginitis. Dermatol Ther 2010;23:514-522.
35. Dezzutti CS, Brown ER, Moncla B, Russo J, Cost M, Wang L, Uranker K, Kunjara Na Ayudhya RP, Pryke K, Pickett J, Leblanc MA, Rohan LC. Is wetter better? An evaluation of over-the-counter personal lubricants for safety and anti-HIV-1 activity. PLoS ONE 2012;7:e48328. doi: 10.1371/journal.pone.0048328.